CFA
BEAM icon

Carroll Financial Associates’s Beam Therapeutics BEAM Stock Holding History

Carroll Financial Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$8K – 1692
2021
Q1 		$8K Buy
+100
New +$9.51K ﹤0.01% 1259

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carroll Financial Associates's BEAM Position: Q2 2021 in Review

Carroll Financial Associates sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 100 shares — an estimated $8K sold.

Carroll Financial Associates first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $8K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Carroll Financial Associates reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 100 Beam Therapeutics shares in Q2 2021, an estimated $8K.
  • Carroll Financial Associates first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
  • Carroll Financial Associates's Beam Therapeutics position peaked at $8K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Carroll Financial Associates's 13F filing for Q2 2021, filed 13 Jul 2021.